Emerging and future therapies for nonalcoholic steatohepatitis in adults.
about
Non-alcoholic fatty liver disease: An expanded reviewSalidroside Modulates Insulin Signaling in a Rat Model of Nonalcoholic Steatohepatitis.BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosisIrisin in metabolic diseases.Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
P2860
Emerging and future therapies for nonalcoholic steatohepatitis in adults.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Emerging and future therapies for nonalcoholic steatohepatitis in adults.
@en
type
label
Emerging and future therapies for nonalcoholic steatohepatitis in adults.
@en
prefLabel
Emerging and future therapies for nonalcoholic steatohepatitis in adults.
@en
P2860
P1476
Emerging and future therapies for nonalcoholic steatohepatitis in adults.
@en
P2093
Gesthimani Mintziori
Stergios A Polyzos
P2860
P304
P356
10.1080/14656566.2016.1225727
P407
P577
2016-08-26T00:00:00Z